Mercado de alimentos médicos da Ásia-Pacífico para erros inatos do metabolismo – Tendências do setor e previsão para 2030

Alimentos médicos da Ásia-Pacífico para erros inatos da análise e tamanho do mercado do metabolismo

O consumo de suplementos nutracêuticos e de alimentos médicos recomendados está a aumentar em relação aos medicamentos à base de enzimas. Prevê-se que a tendência de abandono dos medicamentos e de suplementos dietéticos e alimentos medicinais mude como resultado do aumento dos custos de saúde e da preferência dos clientes por soluções rápidas e fáceis de gestão de doenças. A procura de alimentos médicos aumentou em relação ao ano anterior devido ao aumento das despesas com alimentos médicos e à introdução de novos produtos para novas indicações.

A Data Bridge Market Research analisa que o valor de mercado dos alimentos médicos para erros congénitos do metabolismo é de 531,59 milhões de dólares em 2022, devendo atingir 1.354,28 milhões de dólares até 2030, com um CAGR de 12,4% durante o período de previsão de 2023 a 2030. Além de os insights sobre cenários de mercado, tais como valor de mercado, taxa de crescimento, segmentação, cobertura geográfica e grandes players, os relatórios de mercado com curadoria da Data Bridge Market Research também incluem análise especializada aprofundada, epidemiologia dos doentes, análise de pipeline, análise de preços e enquadramento regulamentar .

Alimentos médicos da Ásia-Pacífico para erros inatos do âmbito e segmentação do mercado do metabolismo  

Definição de mercado

O termo "alimento medicinal" foi cunhado pela Lei dos Medicamentos Órfãos, que foi alterada em 1988, e instruiu a FDA para desenvolver regulamentos que permitam que tais formulações alimentares especializadas sejam utilizadas sob supervisão médica para a gestão nutricional de uma doença ou condição com base clinicamente estabelecida. Algumas doenças conhecidas como anomalias metabólicas congénitas que ocorrem quando o organismo é incapaz de transformar os alimentos em energia. As mutações genéticas resultam na diminuição ou ausência da síntese de uma determinada enzima que decompõe compostos específicos. Existem dificuldades significativas devido à acumulação de compostos nocivos. Recebem dietas específicas, muitas vezes conhecidas como refeições medicinais, sob a supervisão de médicos, a fim de tratar estas condições.

Alimentos médicos da Ásia-Pacífico para erros inatos da dinâmica do mercado do metabolismo

Motoristas

• Aumento da preferência por suplementos dietéticos

Contrary to enzyme-based therapeutic drugs, nutritional supplements and foods that have been prescribed for medical purposes are growing in popularity. Rising healthcare expenses and consumer preference for rapid, low-cost and effective disease treatment approaches are most likely to blame for the trend away from pharmaceuticals and toward dietary supplements and therapeutic foods. The term "medical food" refers to a class of products that are used in the nutritional management of a number of disorders including inborn metabolic abnormalities, and that include certain nutrients to match the nutrient requirements of patients with particular illnesses. These specific factors are drive the market's expansion.

Opportunities

• Rising use of medical foods

The market is regulated by authoritative and medical foods are employed as therapy choices for inborn metabolic abnormalities. Between 85% and 90% of a person's dietary requirements are satisfied by the nutritional therapy for congenital metabolic abnormalities. These supplements are also almost completely side effect-free, making them safe for people of all ages. Private medical insurance in the US and a few other nations have recently started to provide reimbursement programmes for the use of specific medical meals. As a result, market expansion during the forecast period is anticipated to be driven by increased usage of medical food and nutrient supplements.

Restraints/Challenges

• High cost of medical foods

Medical foods are created for people who have difficulty swallowing, digesting, absorbing or metabolising regular foods or nutrients and whose nutritional management cannot be accomplished solely by altering their regular diet. Many health insurance policies in the U.S. do not adequately cover medical foods and without insurance many families cannot afford their high cost.

This medical foods for inborn errors of metabolism market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the medical foods for inborn errors of metabolism market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent developments

• In 2019, In the Netherlands, Nutricia established a sustainable facility. The large investment in the Nutricia Cuijk facility raised the production of specialized infant formula and the market's income.
• In 2022, Mead Johnson & Company, LLC announced that it had merged entirely with Reckitt Benckiser Group plc (RB). It was anticipated that the Mead Johnson brand and business would continue to grow to the effective innovation and marketing practices used by Reckitt Benckiser plc businesses.

Asia-Pacific Medical Foods for Inborn Errors of Metabolism Market Scope

The medical foods for inborn errors of metabolism market is segmented on the basis of products, age group, diseases, forms, packaging and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Products

• Amino Acid
• Glytactin with GMP Amino Acid-Modified Infant Formula with Iron
• Low-Calcium/Vitamin D-Free Infant Formula with Iron
• Low Protein Food
• Others

 Age Group

• Infants
• Weaning
• Adolescent
• Adults

 Diseases

• Phenylketonuria (PKU)
• Maple Syrup Urine Disease (MSUD)
• Homocystinuria
• Methylmalonic Acidemia
• Organic Acidurias
• Propionic Acidemia
• Isovaleric Acidemia
• Disorders of Leucine Metabolism
• Glutaric Acidemia Type I Renal Disease
• Tyrosinemia Types I and II
• Urea Cycle Disorders
• Others

 Forms

• Powder
• Liquids
• Gels
• Others

 Packaging

• Can
• Jar
• Packets
• Bottle
• Others

Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies
• Drugs Stores
• Online Pharmacies
• Others

Medical Foods for Inborn Errors of Metabolism Market Regional Analysis/Insights

The medical foods for inborn errors of metabolism market is analyzed and market size insights and trends are provided by country, products, age group, diseases, forms, packaging and distribution channel as referenced above.

The countries covered in the medical foods for inborn errors of metabolism market report are China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC).

Germany is dominating the medical foods for inborn errors of metabolism market due to the increase in the number of new-born screening procedures and a rise in the number of medical food recommendations from doctors.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

O mercado de alimentos médicos para erros inatos do metabolismo também fornece análises de mercado detalhadas para o crescimento de cada país em gastos de saúde para equipamentos de capital, base instalada de diferentes tipos de produtos para alimentos médicos para erros inatos do mercado de metabolismo, impacto da tecnologia usando curvas de linha de vida e mudanças nos cenários regulamentares de saúde e o seu impacto no mercado de alimentos médicos para erros congénitos do metabolismo. Os dados estão disponíveis para o período histórico 2011-2021.

Cenário competitivo e alimentos médicos para erros inatos da análise da quota de mercado do metabolismo

O cenário competitivo do mercado de alimentos médicos para erros inatos do metabolismo fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, presença na Ásia-Pacífico, localizações e instalações de produção, capacidades de produção, pontos fortes e fracos da empresa, lançamento de produtos, largura e amplitude do produto , dominância da aplicação. Os dados acima fornecidos estão apenas relacionados com o foco das empresas relacionado com o mercado de alimentos médicos para os erros congénitos do metabolismo.

Alguns dos principais players que operam no mercado de alimentos médicos para erros inatos do metabolismo são:

• Nestlé Health Science (Suíça)
• Nutricia (Holanda)
• Consolo Nutrição (EUA)
• Abbott (EUA)
• Mead Johnson & Company, LLC. (NÓS)
• BioMarin Farmacêutica (EUA)
• Ajinomoto Cambrooke, Inc.
• Poa Pharma (Suécia)
• PKU-MDmil (EUA)
• Dr.Schar AG/SPA Primus Pharmaceuticals, Inc.
• A Pristine Organics Unip. Lda. (Índia)
• ABRIL (EUA)
• Ener-G Foods (EUA)
• Promin Metabolics (Reino Unido) 

SKU-53801